MedTrace Logo

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

NCT01745224 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-12-04

No results posted yet for this study

Summary

This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage

Conditions

  • Melasma

Interventions

DEVICE

Revlite Q switched Nd:YAG

Revlite Q switched Nd:YAG 1064nm

DEVICE

Trivantage Q switched Nd: YAG

Trivantage Q switched Nd: YAG 1064nm

Sponsors & Collaborators

  • Cynosure, Inc.

    lead INDUSTRY

Principal Investigators

  • Patricia Krantz · Cynosure, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01745224 on ClinicalTrials.gov